West Pharma (WST) Tops Q2 EPS by 72c; Raises Outlook

West Pharma (NYSE: WST) reported Q2 EPS of $2.46, $0.72 better than the analyst estimate of $1.74. Revenue for the quarter came in at $723.6 million versus the consensus estimate of $669.38 million.

GUIDANCE:

West Pharma sees FY2021 EPS of $8.05-$8.20, versus the consensus of $7.14. West Pharma sees FY2021 revenue of $2.76-2.785 million, versus the consensus of $2.68 million.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance